The 2023 San Antonio Breast Cancer Symposium took place from Dec. 5 to 9, 2023. The five-day conference brought together experts in medical, surgical, gynecologic, and radiation oncology as well as patient advocates to discuss the latest thinking on the biology, etiology, prevention, diagnosis, and treatment of breast cancer and premalignant breast disease.
The Relation Between Excess Adiposity and Breast Cancer in Women: Clinical Implications and Management
Source : https://www.sciencedirect.com/science/article/pii/S1040842823003013?via=ihub
Breast cancer (BC) is the most common cancer in women. While the combination of improved screening, earlier detection, and advances in therapeutics ha...
Weight gain prevention and weight loss interventions should ideally be seamlessly included in the management of breast cancer to provide a holistic, individualized approach to improve health and survival in this population.
Young Women With Breast Cancer: the Current Role of Precision Oncology
Source : https://www.mdpi.com/2075-4426/13/11/1620
Young adults aged 40 years and younger with breast cancer represent less than 5% of all breast cancer cases, yet it is the leading cause of death among young women...
Approximately one-half of young adults with breast cancer diagnosed before 30 years have germline BRCA1, BRCA2, or TP53 mutations.
The 2023 San Antonio Breast Cancer Symposium is well underway and taking place from Dec. 5 to 9, 2023. The five-day conference, now in its 46th year, welcomes more than 10,000 researchers, health care professionals, and breast cancer advocates to learn about the latest advancements in diagnosing and treating breast cancer and premalignant breast disease.
Real-World Impact of Dual Anti-HER2 Antibodies on Cardiac Function in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38007881/
Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Among patients with HER2-positive MBC treated with the CLEOPATRA regimen, the real-world incidence of dual anti-HER2 antibodies related LVSD was low.

